Dr. Peter McCullough has expressed concerns about the use of mRNA technology in vaccines beyond emergency situations, specifically for routine vaccinations in children and adults.
McCullough highlights the safety profile of COVID-19 mRNA vaccines and the lack of testing for long-term side effects.
Additionally, Moderna has received FDA approval for their mRNA RSV vaccine, mRESVIA, without the full dossier of safety information typically required for routine approval. This approval sets a new precedent, allowing synthetic mRNA vaccines to bypass previous safety standards.
There are numerous safety concerns associated with pseudouridinated, synthetic mRNA products, including myocarditis, auto-immunity, genomic integration, and oncogenicity.
